Cyrus Biotechnology Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$2.69M
- Investors
-
22
Cyrus Biotechnology General Information
Description
Operator of a biotech company designed to combine protein design and screening to create novel biologics for serious unmet medical needs. The company's software provides a portal for protein structure prediction, modeling, stabilization, engineering, and design to accelerate the discovery of biology and small molecules, enabling users to get assistance in molecular, homology, and protein modeling.
Contact Information
Website
www.cyrusbio.comCorporate Office
- 3005 1st Avenue
- Suite 203
- Seattle, WA 98121
- United States
Corporate Office
- 3005 1st Avenue
- Suite 203
- Seattle, WA 98121
- United States
Cyrus Biotechnology Timeline
Cyrus Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series C) | 28-Feb-2024 | $2.69M | Completed | Pre-Clinical Trials | ||
| 6. Later Stage VC (Series B) | 05-Oct-2021 | Completed | Pre-Clinical Trials | |||
| 5. Debt - PPP | 15-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 27-Jul-2017 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 17-Feb-2017 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 01-Jan-2016 | $225K | Completed | Pre-Clinical Trials | ||
| 1. Grant | 12-Dec-2014 | $50K | Completed | Startup |
Cyrus Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 5,637,827 | $0.000100 | 8% | $0.7 | $0.7 | 1x | $0.7 | 10.65% |
Cyrus Biotechnology Comparisons
Industry
Financing
Details
Cyrus Biotechnology Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Iambic Therapeutics | Venture Capital-Backed | San Diego, CA | ||||
| EpiVax | Venture Capital-Backed | Providence, RI | ||||
| AbCellera | Formerly VC-backed | Vancouver, Canada | ||||
| Exscientia | Pending Transaction (M&A) | Oxford, United Kingdom | ||||
| Recursion Pharmaceuticals | Formerly VC-backed | Salt Lake City, UT |
Cyrus Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cyrus Biotechnology Patents
Cyrus Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4401832-A1 | Engineered receptors and monoclonal antibodies for coronaviruses and uses thereof | Pending | 15-Sep-2021 |
Cyrus Biotechnology Executive Team (5)
| Name | Title | Board Seat |
|---|---|---|
| Lucas Nivon Ph.D | Co-Founder, Chief Executive Officer & Board Member | |
| Yifan Song Ph.D | Co-Founder, Chief Science Officer & Board Member | |
| David Baker | Scientific Co-Founder & Advisor |
Cyrus Biotechnology Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carl Gordon Ph.D | OrbiMed | Board Observer | |
| Chad Waite Jr. | The W Fund | Board Member | |
| Eric Bell | SpringRock Ventures | Board Observer | |
| Eric Larsen | Alliance of Angels | Board Observer & Advisor | |
| Geeta Vemuri Ph.D | Agent Capital | Board Observer |
Cyrus Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cyrus Biotechnology Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria (US) | Corporation | Minority | ||
| Alliance of Angels | Angel Group | Minority | ||
| Agent Capital | Venture Capital | Minority | ||
| Alumni Ventures | Venture Capital | Minority | ||
| Argonautic Ventures | Venture Capital | Minority |
Cyrus Biotechnology FAQs
-
When was Cyrus Biotechnology founded?
Cyrus Biotechnology was founded in 2014.
-
Who is the founder of Cyrus Biotechnology?
Lucas Nivon Ph.D, Yifan Song Ph.D, David Baker, and Javier Castellanos Ph.D are the founders of Cyrus Biotechnology.
-
Who is the CEO of Cyrus Biotechnology?
Lucas Nivon Ph.D is the CEO of Cyrus Biotechnology.
-
Where is Cyrus Biotechnology headquartered?
Cyrus Biotechnology is headquartered in Seattle, WA.
-
What is the size of Cyrus Biotechnology?
Cyrus Biotechnology has 25 total employees.
-
What industry is Cyrus Biotechnology in?
Cyrus Biotechnology’s primary industry is Biotechnology.
-
Is Cyrus Biotechnology a private or public company?
Cyrus Biotechnology is a Private company.
-
What is Cyrus Biotechnology’s current revenue?
The current revenue for Cyrus Biotechnology is .
-
How much funding has Cyrus Biotechnology raised over time?
Cyrus Biotechnology has raised $31.1M.
-
Who are Cyrus Biotechnology’s investors?
Alexandria (US), Alliance of Angels, Agent Capital, Alumni Ventures, and Argonautic Ventures are 5 of 22 investors who have invested in Cyrus Biotechnology.
-
Who are Cyrus Biotechnology’s competitors?
Iambic Therapeutics, EpiVax, AbCellera, Exscientia, and Recursion Pharmaceuticals are some of the 17 competitors of Cyrus Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
